TY - JOUR
T1 - Materials and Cytokines in the Healing of Diabetic Foot Ulcers
AU - Kim, Ka Kyung
AU - Mahajan, Aryan
AU - Patel, Kamiya
AU - Syed, Shareef
AU - Acevedo-Jake, Amanda M.
AU - Kumar, Vivek A.
N1 - Funding Information:
This work was supported by grants NIH R15 EY029504 01A1S1 for AAJ; NIH R15 EY029504, NSF IIP 1903617, the NJIT Undergraduate Research and Innovation (URI) Program for VAK.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2021/9
Y1 - 2021/9
N2 - Diabetes affects an increasing number of patients, and is associated with sustained and chronic inflammation. Complications arising from diabetes, including hypoxia, neuropathy, hyperglycemia, and ischemia that contribute to a delayed and reduced healing response result in chronic slow healing wounds. Here, key differences in native versus diabetic wound healing during each phase of healing are discussed, and the roles of cells and their secreted cytokines which regulate this process are outlined. Monocyte chemoattractant protein-1 (MCP-1) is a pro-inflammatory mediator which plays a key role in modulating angiogenesis. Its importance in diabetic wound healing as well as recent work using MCP-1 and similar chemokines to reduce inflammation and improve healing are reviewed. The delayed healing response observed in diabetic patients often results in the formation of slow healing wounds, commonly presenting in the lower extremities as diabetic foot ulcers (DFUs); classification systems and current treatment options for DFUs, including debridement, off-loading, and amputation are outlined. Common dressing strategies are highlighted, and recent work developing biocompatible and bioactive hydrogels to address and hasten chronic wound healing is focused on.
AB - Diabetes affects an increasing number of patients, and is associated with sustained and chronic inflammation. Complications arising from diabetes, including hypoxia, neuropathy, hyperglycemia, and ischemia that contribute to a delayed and reduced healing response result in chronic slow healing wounds. Here, key differences in native versus diabetic wound healing during each phase of healing are discussed, and the roles of cells and their secreted cytokines which regulate this process are outlined. Monocyte chemoattractant protein-1 (MCP-1) is a pro-inflammatory mediator which plays a key role in modulating angiogenesis. Its importance in diabetic wound healing as well as recent work using MCP-1 and similar chemokines to reduce inflammation and improve healing are reviewed. The delayed healing response observed in diabetic patients often results in the formation of slow healing wounds, commonly presenting in the lower extremities as diabetic foot ulcers (DFUs); classification systems and current treatment options for DFUs, including debridement, off-loading, and amputation are outlined. Common dressing strategies are highlighted, and recent work developing biocompatible and bioactive hydrogels to address and hasten chronic wound healing is focused on.
KW - bioactive materials
KW - cytokines
KW - diabetic foot ulcers
KW - hydrogels
KW - monocyte chemoattractant protein-1
KW - wound dressings
UR - http://www.scopus.com/inward/record.url?scp=85109340296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109340296&partnerID=8YFLogxK
U2 - 10.1002/adtp.202100075
DO - 10.1002/adtp.202100075
M3 - Review article
AN - SCOPUS:85109340296
SN - 2366-3987
VL - 4
JO - Advanced Therapeutics
JF - Advanced Therapeutics
IS - 9
M1 - 2100075
ER -